News and Events, Recent News

BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference

· Interim data indicate an excellent safety profile for the combination regimen in advanced breast cancer patients. Initial efficacy data is expected in first quarter of 2019; · Confirmed positive proof-of-concept with Bria-IMT™ Monotherapy demonstrates promising anti-tumor activity with excellent safety and tolerability in advanced breast cancer patients. BERKELEY, Calif., and VANCOUVER, British Columbia, December […]

News and Events, Recent News

UPDATED – BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

Note: This Press Release contains amendments to the press release previously issued on Nov. 19, 2018 · Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by […]

News and Events, Recent News

BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

· Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) in advanced breast cancer. · Interim safety data of the combination study […]

News and Events, Recent News

BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®

· Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) or YERVOY® (by Bristol-Myers Squibb Company) in advanced breast cancer. · KEYTRUDA® and YERVOY® have been highly recognized for their potent immune boosting properties – Nobel Prize in Medicine 2018 – validating BriaCell’s strategy to use these […]

News and Events, Recent News

BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study

· BriaCell has achieved positive proof of concept in the Phase IIa study of Bria-IMT™ in advanced breast cancer patients · Data shows promising anti-tumor activity of Bria-IMT™ in heavily pre-treated advanced breast cancer patients · Impressive Phase IIa efficacy data is similar or superior to those of other approved breast cancer drugs of similar […]

News and Events, Recent News

BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences

– Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which is key to the advancement of BriaCell’s BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment. – Phase I/IIa clinical efficacy data will be announced in advance of these conferences. (Accesswire — September […]

News and Events, Recent News

BriaCell Adds New Clinical Site To Phase IIa Study in Advanced Breast Cancer and Expands R&D Team

• The addition of the Cancer Center of Kansas (CCK) as a new clinical trial site is expected to accelerate patient enrollment in both clinical trials. • The hiring of Dr. Sunkari, an experienced Scientist, is intended to speed up the development of Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy. BERKELEY, Calif. and VANCOUVER, British Columbia, […]

News and Events, Recent News

BriaCell to Hold Conference Call on Key Clinical Findings; Activities

BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a Corporate Update on its activities and new developments, including positive Phase IIa safety information, discovery of tumor shrinkage mechanism, and patient […]

News and Events, Recent News

BriaCell Therapeutics Corp. to Present at The MicroCap Conference on June 21st in Toronto at the Sheraton Centre Hotel

(Accesswire — June 13, 2018) – BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will be presenting at this year’s MicroCap Conference on June 21st in Toronto, Canada. Dr. Bill Williams, BriaCell’s President and CEO will discuss Bria-IMT™, BriaCell’s lead clinical candidate, its potential in […]